GenFleet Therapeutics (Shanghai) (HAM:Y3L) Institutional Ownership: 8.73% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Institutional Ownership?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Institutional Ownership is 8.73% as of Aug. 04, 2026. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GenFleet Therapeutics (Shanghai)'s institutional ownership is 8.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GenFleet Therapeutics (Shanghai)'s Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GenFleet Therapeutics (Shanghai)'s Float Percentage Of Total Shares Outstanding is 0.00%.

GenFleet Therapeutics (Shanghai) Institutional Ownership Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Institutional Ownership Chart

GenFleet Therapeutics (Shanghai) Historical Data

The historical data trend for GenFleet Therapeutics (Shanghai) can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 4.60 4.78 6.50 6.00 6.07 8.84 8.71 8.86 9.00 8.73
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 8.73% mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Institutional Ownership of 8.73% as of Aug. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s Institutional Ownership too high?
GenFleet Therapeutics (Shanghai)'s current Institutional Ownership is 8.73%. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Institutional Ownership compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Institutional Ownership of 8.73% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Institutional Ownership is 8.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Institutional Ownership of 8.73%. The current Institutional Ownership is 8.73%. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Institutional Ownership is 8.73% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price